The clinical role of combined serum C1q and hsCRP in predicting coronary artery disease
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 93, 50-58
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality (7182047)
- National Natural Science Foundation of China (81670322)
This publication has 44 references indexed in Scilit:
- A Dramatic Increase of C1q Protein in the CNS during Normal AgingThe Journal of Neuroscience, 2013
- Pathogen-Mediated Inflammatory Atherosclerosis Is Mediated in Part via Toll-Like Receptor 2-Induced Inflammatory ResponsesJournal of Innate Immunity, 2010
- Complement C1q Activates Tumor Suppressor WWOX to Induce Apoptosis in Prostate Cancer CellsPLOS ONE, 2009
- C1q and its growing familyImmunobiology, 2007
- Complement C1q Reduces Early Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient MiceThe American Journal of Pathology, 2007
- Effect of Modified C-Reactive Protein on Complement ActivationArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- C-reactive protein binds to the 3β-OH group of cholesterol in LDL particlesBiochemical and Biophysical Research Communications, 2005
- Expression of gC1q-R/p33 and its major ligands in human atherosclerotic lesionsMolecular Immunology, 2004
- A more meaningful scoring system for determining the severity of coronary heart diseaseThe American Journal of Cardiology, 1983